Research Article

Greenselect Phytosome for Borderline Metabolic Syndrome

Gianni Belcaro, Andrea Ledda, Shu Hu, Maria Rosa Cesarone, Beatrice Feragalli, and Mark Dugall

Department of Biomedical Sciences, Irvine3 Circulation/Vascular Labs & San Valentino Vascular Screening Project, Gabriele D’Annunzio University, Chieti, Italy

Received 22 July 2013; Revised 26 September 2013; Accepted 27 September 2013

Academic Editor: Mohamed Eddouks

Copyright © 2013 Gianni Belcaro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The beneficial effects of Greenselect Phytosome, a proprietary lecithin formulation of a caffeine-free green tea catechin extract, were evaluated in a controlled registry study on 50 asymptomatic subjects borderline for metabolic syndrome factors and with increased plasma oxidative stress. After 24 weeks of intervention, improvement in weight, blood lipid profile, and blood pressure positioned 68% of subjects in the treatment arm out of the metabolic syndrome profile, while 80% of the subjects in the control group still remained in their initial borderline disease signature. Compared to the control (lifestyle and dietary changes alone), Greenselect Phytosome was especially effective for weight/waist changes. These results highlight the relevance of addressing multiple factors involved in the development of metabolic syndrome with a pleiotropic agent capable of improving the beneficial effects of lifestyle and dietary changes and foster the attainment of a globally improved health profile.

1. Introduction

Tea is probably the most consumed beverage in the world after water, and its pharmacological potential has been extensively investigated [1]. The phytochemical profile of tea depends on the extent of oxidation (fermentation in the tealingo) of its catechin constituents, and most studies have focused on green tea that maintains the original polyphenolic profile of the leaves and is the source of sainecatechins, a registered drug for the topical management of genital warts [1]. Cancer prevention [2, 3], weight loss [4, 5], and diabetes [6–9] are some of the other hot areas of clinical investigation where green tea catechins have proved potentially useful both as a stand-alone agent and in combination with lifestyle and pharmacological intervention strategies.

According to an estimation from 2010 [10], more than 35% of adults and 17% of children and adolescents are medically obese (BMI > 30) in North America, and obesity rates are rapidly increasing not only in affluent Western countries but also in poorer nations, presumably because of the growing popularity of the obesogenic Western lifestyle [11, 12]. Green tea extracts enriched in catechins have shown promising results in reducing body mass index in over-weight subjects, especially when associated with lifestyle changes and diet [13–18]. A synergistic effect of catechins and caffeine on reducing obesity has been observed, presumably due to a complementary increase in adrenergic tone and its associated signal translation in adipose tissue [19], but the detrimental effects of caffeine on glucose control and blood pressure make this association questionable in the context of overall prevention of the metabolic syndrome (MetS) [20]. Thus, obesity is often associated, especially in adults, with detrimental changes in glucose control and variously related cardiovascular risk factors (dyslipidemia, hypertension). Epigallocatechin gallate (EGCG), the major catechin of green tea, is a well-known thermogenic agent [21] that, unlike caffeine, also shows beneficial effects toward several markers of the metabolic syndrome, especially glucose control and dyslipidemia [22].

Greenselect Phytosome (GSP) is a green tea extract devoid of caffeine and formulated in lecithin to improve the absorption of catechins [23]. Because of its domesticated profile compared to other green tea extracts in terms of phytochemical profile and bioavailability, it was selected, in the form of coated tablets (Monoselect Camellia, MonCam), for a single blind, controlled study on 50 asymptomatic subjects borderline for all five MetS factors, who were also showing an
increased plasma oxidative stress. According to the new International Diabetes Federation (IDF) definition [24], metabolic syndrome patients are featuring central obesity as well as two (or more) of the following four factors:

(i) raised triglycerides level: ≥150 mg/dL (1.7 mmol/L) or need for treatment for this lipid abnormality;

(ii) reduced HDL cholesterol: <40 mg/dL (1.03 mmol/L) in males and <50 mg/dL (1.29 mmol/L) in females or need for treatment for this lipid abnormality;

(iii) raised blood pressure: systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg or treatment of previously diagnosed hypertension;

(iv) raised fasting plasma glucose: FPG ≥ 100 mg/dL (5.6 mmol/L) or previously diagnosed Type II diabetes.

MetS is associated with an increased risk of cardiovascular events (i.e. coronary disease, myocardial infarction, and stroke) and to the development of type-2 diabetes [25–28]; its management should be aggressive, constant, and effective, involving primary intervention (lifestyle modification with calorie restriction, increase of physical activity, and change in dietary composition) to achieve a 10% loss of body weight in the first year. Even a modest weight loss is associated with a significant risk reduction for Type II diabetes and cardiovascular disease [29–31]. When lifestyle change is not possible or not adequate and in subjects considered at higher risk for cardiovascular disease, a secondary intervention [32–34] resorting to drug therapy may be required to treat MetS, and there is a dire need of agents to control its risk factors. However, since the actual molecular mechanism(s) underlying the development of MetS are still largely elusive, no specific pharmacological agents are currently available to globally control the cardiovascular and diabetic risk associated to MetS [35–37]. The relevance of each single factor in the development of metabolic syndrome is indeed difficult to evaluate and might even be different in distinct populations [32, 38]. In the present study, we wanted to evaluate whether GSP is able to support the beneficial effects of lifestyle and dietary changes and foster the attainment of a globally improved health profile, thanks to its pleiotropic effect able to address multiple factors involved in the development of metabolic syndrome.

2. Materials and Methods

2.1. Subjects. Inclusion criteria were an asymptomatic status, a borderline profile for all the 5 MetS factors, and an increased oxidative stress. Exclusion criteria for subjects were fasting blood glucose values exceeding 162 mg/dL and any other metabolic or clinical conditions requiring medical treatment. Pregnant or breastfeeding females, individuals with any clinical condition, psychiatric disorders including depression, and subjects who participated in another study less than 30 days before the start of this study were excluded as well.

2.2. Study Design. The present study was randomized, single-blinded, parallel design comparing GSP tablets versus a corresponding blank formulation, in association with lifestyle and dietary interventions.

2.3. Study Protocol. At inclusion, subjects were unaware of the presence of MetS and of the value of the MetS factors. The study was performed according to the Declaration of Helsinki, and all patients gave an informed consent prior to their participation to the study. After briefing and evaluation of their interest to participate in the study, the volunteers were divided into two groups using the same management plans.

(i) Group 1: management plan + MonCam (1 tablet at 10 AM and one at 6 PM) equivalent to overall 300 mg/day of GSP.

(ii) Group 2: management plan + corresponding blank formulation.

Volunteers had a defined management plan: changes in diet, thus avoiding junk food and limiting high calorie elements, and a precise individual exercise plan. Diet produced a caloric deficit (750 kcal/day in females and 1000 kcal/day in males) compared to the individual estimated energy requirements and contained 17–22% proteins, 23–25% fats, and 55–58% carbohydrates. Individual exercise plan foresaw 210 minutes/week of physical activity (70% moderate aerobic, 30% muscular strengthening). None of the included subjects had important (at ultrasound scans) atherosclerotic lesions (plaques or intima-media thickening) in the studied arteries (carotids, femoral, aorta). No other nutritional elements, vitamins, or drugs were used in the observation period. No other clinical condition was present.

Based upon published data about the efficacy of lifestyle changes on MetS [39, 40], an estimate of not less than 25 subjects completing the study in each group was considered necessary to obtain clinically meaningful data on the treatment outcome. The safety population, as planned in the protocol, was effectively composed of all the subjects recruited into the study, who received at least one dose (product or blank formulation) and having at least one post baseline safety evaluation (one week). The intention-to-treat (ITT) efficacy analysis included all the subjects who had received at least one dose of medication and had had at least one post baseline measurement of the primary efficacy items. Subjects having treatment compliance <70% were excluded. The ITT analysis was performed comparing “all treated subjects” versus control subjects. The per-protocol (PP) analysis had to include all subjects available for the ITT analysis, who completed the planned duration of treatment, were complying with the regimen, had a valid efficacy evaluation, and did not violate the protocol in any way liable to influence the efficacy outcome. A range of compliance of at least 85% was adopted as a criterion to select subjects for the PP analysis. Therefore, subjects with compliance <85% were excluded, as well as all the subjects who did not meet the criteria for the “Population for efficacy analysis.” Additional (“post-hoc”) analysis was made to assess the minimum effective time “dose” to reach significant results. These tests were performed using closed testing procedures. The fixed-sequence Dunnett test was applied to determine the time...
needed to have results on each MetS item. All hypothesis tests were two sided. All statistical tests (nonparametric) were performed at a 5% significance level ($P < 0.05$).

2.4. Products. Both the ingredient Greenselect Phytosome (GSP) and its oral formulation in tablets Monoselect Camellia (MonCam) are commercially available products from Indena (Milan, Italy) and from PharmExtracta (Pontenure, Italy), respectively. GSP is a decaffeinated, standardized extract from green tea having the following specifications:

(i) epigallocatechin-3-O-gallate (EGCG) $\geq 13\%$;
(ii) polyphenols $19\%$–$25\%$;
(iii) caffeine $\leq 0.1\%$.

Each MonCam tablet has been manufactured to contain 150 mg of GSP. No side effects were reported during the execution of the study, formulation tolerability (both for GSP and the corresponding blank formulation) being excellent, with overall more than 93% of GSP tablets and more than 91% of blank formulation having been correctly used.

2.5. Blood Tests. At inclusion and at 24 weeks (end of observation), a panel of additional blood tests was carried out (ALT, AST, gamma-GT, Alkaline Phosphatase, CRP, Serum creatinine, Leptin as well as blood cell count and fibrinogen, aPTT, and PT-Quick’s value and hematocrit).

2.6. Anthropometric Measures. At inclusion and at 24 weeks (end of observation) the following anthropometric parameters were taken in all subjects: body weight, body mass index (BMI), and waist circumference.

2.7. Data Analysis. The clinical efficacy assessed by weight and blood test score was examined using a B-W-Subject Anova model, a mixed analysis of variance design for differences mean, which is the only model that can be correctly applied to the experimental data [41]. Analysis of difference between active and blank formulation groups was performed by Tukey-Kramer test for pairwise comparisons between means.

3. Results and Discussion

We have been interested in the possibility to improve the outcome of MetS primary prevention by complementing lifestyle changes with dietary ingredients capable to address the various dysfunctions in which the syndrome is declined, and, as discussed above, green tea catechins show indeed the potential to do so. To explore this enticing possibility, we hence carried out a single blind controlled study on 50 asymptomatic subjects borderline for all the five mentioned MetS factors and also showing increased plasma oxidative stress. The study lasted 24 weeks, and 48 (25 men and 23 women) out of 50 subjects in the treatment group completed the study, with no dropouts being due to medical reasons; 50 comparable control volunteers were also followed for all the duration of the study, with no dropouts. The groups characteristics are summarized in Table I.

The results, which are detailed in Table 2, confirmed the efficacy of the management plan to achieve an overall amelioration, both at the anthropometric and blood parameters level. Compared to the control group, though, who took the blank formulation, the group who took MonCam performed remarkably better, achieving for all the parameters observed a better outcome, statistically significant both versus the baseline and versus the control group, even for items where the control group did not obtain a significant result (waist circumference in women, HDL cholesterol, blood pressure, and fasting glucose).

The panel of additional blood tests did not show any significant variations (within the normal range at inclusion and after the evaluation period, as may be expected in borderline volunteers).

GSP clearly promoted weight loss and reduced waist circumference (see Table 2) when compared to management plan alone. The improvement in GSP subjects in borderline MetS was also associated with lipids and blood pressure beneficial variations. Finally, the value of plasma free radicals (PFR) decreased at 24 weeks in the GSP group ($-33.04\%$; $P < 0.05$ versus inclusion) in a much more marked way compared to the control (decreasing only $-4.14\%$; n.s. versus inclusion, $P < 0.022$ between groups).

Overall, GSP appears to have a moderate, yet significant, action on each single parameter of MetS, with particular emphasis on weight/waist changes. It was also interesting to evaluate the global impact of the treatment protocol (lifestyle + GSP versus lifestyle + blank formulation) on the various parameters defining metabolic syndrome (Table 3). In accordance with the inclusion criteria, 100% of subjects had borderline values for all the five parameters of MetS. At the end of the study, 68.75% of GSP subjects (33 out of 48) were outside the metabolic syndrome profile, 7 had reached a limit profile for MetS, while only 8 were still lingering in MetS area. Conversely, in the control group, 80% of subjects were still in MetS area at 24 weeks and 10 out of 50 (20%) had still a borderline profile for MetS. Therefore, a significant improvement in all risk conditions and a more significant progressive exit from the MetS area were observed in the GSP branch. In the ITT analysis, 40 out of a total 48 GSP subjects (83.33%) improved in comparison with 20% of controls (10/50), a statistically significant ($P < 0.02$) difference.

4. Discussion

This study confirms GSP's efficacy in weight loss when associated with proper lifestyle modifications and a low-calorie diet [18]. This result was achieved despite the absence of caffeine in the product, thus going beyond results found with caffeine-containing green tea extracts [19, 22] and confirming that catechins alone can have an important role in controlling weight, most likely through the increase of fat oxidation [21]. Spurred by epidemiological data, some investigations have been undertaken to evaluate the usefulness of green tea and green tea extracts in MetS [42, 43]; for the time being, the heterogeneity of the studies available in literatures
### Table 1: Group characteristics at inclusion.

| Group                                      | Number of subjects | Men/women ratio | Age (average; ± s.d.; range) | Percentage of subjects with borderline MetS values (for all 5 items) |
|--------------------------------------------|--------------------|-----------------|-----------------------------|---------------------------------------------------------------------|
| Treated group (Management plan + MonCam)   | 50                 | 25/25           | 47.6 yr.; ± 5.5; 45–55      | 100%                                                                |
| Control group (Management plan + blank formulation) | 50                 | 24/26           | 45.3 yr.; ± 3.55; 45–55      | 100%                                                                |

### Table 2: Anthropometric and blood parameters in treated and control groups at the inclusion and at the end of the observation period (24 weeks).

| ITEM (inclusion criteria) | Reference for MetS according to NCEP ATP III | Inclusion | 24 weeks | \( P \) |
|---------------------------|----------------------------------------------|-----------|----------|-------|
| Weight (kg)               | GSP                                          | 88.4; 2.4 | 76.6; 2.5 | * #   |
|                           | range                                        | 83.2–92.5| 72.3–82.8|       |
|                           | control                                      | 88.9; 2.1| 83.0; 1.8|       |
|                           | range                                        | 84.4–91.3| 87.0–77.6|       |
| BMI                       | GSP                                          | 31.0; 2.0 | 26.7; 1.7| * #   |
| Normal 18.5 to 25         | control                                      | 30.9; 2.6| 28.9; 2.5| *     |
| Overweight 25 to 30       |                                              |           |          |       |
| Central obesity           | GSP                                          | M 107.0; 1.3| 95.6; 1.3| * #   |
| (waist circumference)     | control                                      | M 105.6; 2.5| 101; 2.0 |       |
| >102 cm (men)             |                                              | F 91.0; 1.6| 82.7; 2.3| * #   |
| >88 cm (women)            |                                              | F 90.0; 2.4| 88.5; 2.5|       |
| Fasting glucose           | GSP                                          | 116.1; 5.3| 107.9; 3.0| * #   |
| >110 mg/dL                | control                                      | 115.7; 3.7| 113.7; 3.0| ns    |
| Triglycerides             | GSP                                          | 168.0; 8.7| 154.7; 7.0| * #   |
| >150 mg/dL                | control                                      | 163.8; 8.4| 160.0; 7.3|       |
| HDL cholesterol           | GSP                                          | M 34.4; 2.2| 41.8; 3.3| * #   |
| M < 40 mg/dL              | control                                      | M 36.0; 3.4| 36.7; 3.2| ns    |
| F < 50 mg/dL              |                                              | F 44.5; 3.4| 45.8; 2.0|       |
| Plasma free radicals      | GSP                                          | 466.4; 38 | 312; 42   | * #   |
| Blood pressure            | control                                      | 458.3; 34 | 439.3; 33 | *     |
| Systolic BP > 130 mm Hg   | GSP                                          | Sys 136.8; 4.1| 129.6; 2.1| * #   |
| Diastolic BP > 85 mm Hg   | control                                      | Dia 88.8; 2.9| 83.6; 2.2|       |

\( P < 0.05; * \) better than inclusion; *# better than controls.

### Table 3: MetS factors presence in 98 subjects (48 treated and 50 controls) at inclusion and at the end of the study.

| MetS factors affecting subjects | Inclusion | GSP treated (48) | Controls (50) |
|---------------------------------|-----------|------------------|---------------|
|                                 | subjects  | %                | subjects      | %    |
| Metabolic syndrome area         |           |                  |               |
| 5 over 5                        | 98        | 100%             | 1             | 2%   |
| 4 over 5                        | —         | —                | 2             | 4%   |
| 3 over 5                        | —         | —                | 5             | 10%  |
| Borderline                      |           |                  |               |
| 2 over 5                        | —         | —                | 7             | 15%  |
| Out of metabolic syndrome area  |           |                  |               |
| 1 over 5                        | —         | —                | 11            | 23%  |
| none                            | —         | —                | 22            | 46%  |

\( P < 0.05; * \) better than inclusion; *# better than controls.
and their still limited numbers makes it difficult to compare our results with those obtained in other studies, although featuring coherent outcomes.

In terms of body weight specifically, it is worth mentioning that the results described above were obtained treating volunteers with a dose of GSP corresponding to 40 mg/day catechins, while other studies on green tea and green tea extracts in weight loss area (although in a different type of population) were done treating volunteers with much higher doses of green tea catechins (375–1200 mg/day) typically associated with caffeine (150–600 mg/day) [15, 44–48]. While the exact composition of green tea infusions and green tea extracts used in the studies available from the literature cannot always be clearly identified, we assume that the achievement of a significant weight loss resorting to a catechins intake which is significantly lower than in other studies can be explained by an improved bioavailability provided by the lecithin component of GSP [49]. Also, the use of a standardized, reproducible extract, as in the case of GSP, allows making future comparisons in case of additional clinical experiences in weight loss and MetS.

Another important aspect to be evaluated when comparing studies obtained with different green tea derivatives is the presence of caffeine, in addition to the content, composition, and bioavailability of catechins. The role of caffeine is, in fact, double-edged: if, from one side, it can increase the metabolic rate and calorie expenditure [50], on the other side, it is able to disrupt insulin sensitivity at low doses even in healthy volunteers [51], possibly leading to an undesirable weight loss outcome as a result of these two opposite effects. Hence, we cannot exclude that the absence of caffeine in the tested product may have had an additional positive role in the study.

5. Conclusions

Body weight reduction is considered the hallmark target to reduce the detrimental effects of MetS on health, and the attainment of this aim requires changes in lifestyle and nutrition [52], promoting exercise, and caloric restriction. The increase of calories expenditures obtained by exercise can be complemented by the use of thermogenic food ingredients, that is, compounds that promote brown adipose tissue activity and, in general, the degradation of fats in a non-ATP producing way. Thermogenic compounds could also provide help in counteracting the metabolic homeostatic adjustments associated to diet, increasing its overall efficacy [53]. The effect of green tea, the best-known dietary thermogenic agent, is therefore expected to be most evident when associated to a lifestyle intervention that involves both dietary restriction and exercise. We have evaluated this possibility in a controlled registry study in borderline MetS individuals, associating a lecithin-formulated decaffeinated catechin extract (GSP) to a controlled hypocaloric diet and exercise schedule. Compared to a control characterized by the same lifestyle intervention scheme, significant beneficial effects were observed not only on weight but also on other markers of cardiovascular and diabetic risk associated with the conditions, making it tempting to speculate that green tea might promote these improvements not only indirectly via weight loss but also directly, owing to its antioxidant and anti-inflammatory activity. We believe that the study we have outlined is worth expanding in terms of both recruitment and duration, also focusing on the chronic subclinical inflammation commonly associated with MetS and obesity. Inflammation strongly contributes to the persistence of the MetS and to the clinical consequences of the syndrome [54–58], and inflammatory markers, often in association with an increased oxidative stress, are usually found in MetS, contributing to its progression to higher risk levels [59].

References

[1] S. Bansal, N. Syan, P. Mathur, and S. Choudhary, "Pharmacological profile of green tea and its polyphenols: a review," Medicinal Chemistry Research, vol. 21, no. 11, pp. 3347–3360, 2012.
[2] C. S. Yang and X. Wang, "Green tea and cancer prevention," Nutrition and Cancer, vol. 62, no. 7, pp. 931–937, 2010.
[3] K. Boehm, F. Borrelli, E. Ernst et al., "Green tea (Camellia sinensis) for the prevention of cancer," Cochrane Database of Systematic Reviews, no. 3, Article ID CD005004, 2009.
[4] T. M. Jurgens, A. M. Whelan, L. Killian, S. Doucette, S. Kirk, and E. Foy, "Green tea for weight loss and weight maintenance in overweight or obese adults," Cochrane Database of Systematic Reviews, vol. 12, Article ID CD008650, 2012.
[5] R. Hursel, W. Viechtbauer, and M. S. Westerterp-Plantenga, "The effects of green tea on weight loss and weight maintenance: a meta-analysis," International Journal of Obesity, vol. 33, no. 9, pp. 956–961, 2009.
[6] J. H. Park, J. Y. Jin, W. K. Baek et al., "Ambivalent role of gallocatechins in glucose tolerance in humans: a novel insight into non-absorbable gallocatechin-derived inhibitors of glucose absorption," Journal of Physiology and Pharmacology; vol. 60, no. 4, pp. 101–109, 2009.
[7] K. Maruyama, H. Iso, S. Sasaki, and Y. Fukino, "The association between concentrations of green tea and blood glucose levels," Journal of Clinical Biochemistry and Nutrition, vol. 44, no. 1, pp. 41–45, 2009.
[8] T. Miura, T. Koike, and T. Ishida, "Antidiabetic activity of green tea (Thea sinensis L.) in genetically type 2 diabetic mice," Journal of Health Science, vol. 51, no. 6, pp. 708–710, 2005.
[9] M. E. Waltner-Law, X. L. Wang, B. K. Law, R. K. Hall, M. Nawano, and D. K. Granner, "Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production," Journal of Biological Chemistry, vol. 277, no. 38, pp. 34933–34940, 2002.
[10] C. L. Ogden, M. D. Carroll, B. K. Kit, and K. M. Flegal, "Prevalence of obesity in the United States, 2009-2010," NCHS Data Brief, no. 82, pp. 1–8, 2012.
[11] S. Kumanayika, R. W. Jeffery, A. Morabia, C. Ritenbaugh, and V. J. Antipatis, "Obesity prevention: the case for action," International Journal of Obesity, vol. 26, no. 3, pp. 425–436, 2002.
[12] P. Hossain, B. Kawar, and M. El Nahas, "Obesity and diabetes in the developing world—a growing challenge," The New England Journal of Medicine, vol. 356, no. 3, pp. 213–215, 2007.
[13] M. Bose, J. D. Lambert, J. Ju, K. R. Reuhl, S. A. Shapses, and C. S. Yang, "The major green tea polyphenol, (−)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice," Journal of Nutrition, vol. 138, no. 9, pp. 1677–1683, 2008.
[14] T. Nagao, T. Hase, and I. Tokimitsu, “A green tea extract high in catechins reduces body fat and cardiovascular risks in humans,” *Obesity*, vol. 15, no. 6, pp. 1473–1483, 2007.

[15] A. G. Dulloo, C. Duret, D. Rohrer et al., “Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans,” *American Journal of Clinical Nutrition*, vol. 70, no. 6, pp. 1040–1045, 1999.

[16] S. Wolfram, Y. Wang, and F. Thielecke, “Anti-obesity effects of green tea: from bedside to bench,” *Molecular Nutrition and Food Research*, vol. 50, no. 2, pp. 176–187, 2006.

[17] Q. Shixian, B. VanCrey, J. Shi, Y. Kakuda, and Y. Jiang, “Green tea extract thermogenesis-induced weight loss by epigallocatechin gallate inhibition of catechol-O-methyltransferase,” *Journal of Medicinal Food*, vol. 9, no. 4, pp. 451–458, 2006.

[18] M.-C. Pouliot, J.-P. Despres, S. Lemieux et al., “Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women,” *American Journal of Cardiology*, vol. 73, no. 7, pp. 460–468, 1994.

[19] J. Lindström, A. Louheranta, M. Mannelin et al., “The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity,” *Diabetes Care*, vol. 26, no. 12, pp. 3230–3236, 2003.

[20] J. A. Greenberg, C. N. Boozer, and A. Geliebter, “Coffee, diabetes, and weight control,” *American Journal of Clinical Nutrition*, vol. 84, no. 4, pp. 682–693, 2006.

[21] M. Boschmann and F. Thielecke, “The effects of epigallocatechin-3-gallate on thermogenesis and fat oxidation in obese men: a pilot study,” *The Journal of the American College of Nutrition*, vol. 26, no. 4, pp. 389S–395S, 2007.

[22] C. Gosselin and F. Haman, “Effects of green tea extracts on non-shivering thermogenesis during cold exposure in young men,” *British Journal of Nutrition*, vol. 110, no. 2, pp. 282–288, 2013.

[23] P. Pietta, P. Simonetti, C. Gardana, A. Brusamolino, P. Morazoni, and E. Bombardelli, “Relationship between obesity and plasma antioxidant status,” *Biochemistry and Molecular Biology International*, vol. 46, no. 5, pp. 895–903, 1998.

[24] G. Alberti, P. Zimmet, J. Shaw, and S. M. Grundy, *The IDF Consensus Worldwide Definition of the Metabolic Syndrome*, IDF Communications, Brussels, Belgium, 2006.

[25] E. Bonora, S. Kiechl, J. Willeit et al., “Prevalence of insulin resistance in metabolic disorders: the Bruneck Study,” *Diabetes*, vol. 47, no. 10, pp. 1643–1649, 1998.

[26] J. D. Brunzell and A. F. Ayyobi, “Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus,” *American Journal of Medicine A*, vol. 115, supplement 8, pp. 24S–285S, 2003.

[27] R. W. Nesto, “The relation of insulin resistance syndromes to risk of cardiovascular disease,” *Reviews in Cardiovascular Medicine*, vol. 4, no. 6, pp. S11–S18, 2003.

[28] M.-C. Pouliot, J.-P. Despres, S. Lemieux et al., “Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women,” *American Journal of Cardiology*, vol. 73, no. 7, pp. 460–468, 1994.

[29] J. Lindström, A. Louheranta, M. Mannelin et al., “The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity,” *Diabetes Care*, vol. 26, no. 12, pp. 3230–3236, 2003.

[30] S. J. Robins, D. Collins, J. T. Wittes et al., “Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial,” *Journal of the American Medical Association*, vol. 285, no. 12, pp. 1585–1591, 2001.

[31] J. Tuomilehto, J. Lindström, J. G. Eriksson et al., “Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance,” *The New England Journal of Medicine*, vol. 344, no. 18, pp. 1343–1350, 2001.

[32] A. V. Chobanian, G. L. Bakris, H. R. Black et al., “Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure,” *Hypertension*, vol. 42, no. 6, pp. 1206–1252, 2003.

[33] R. Collins, J. Armitage, S. Parish, P. Sleigh, and R. Peto, “MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial,” *The Lancet*, vol. 361, no. 9374, pp. 2005–2016, 2003.

[34] S. M. Haffner, C. M. Alexander, T. J. Cook et al., “Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the scandinavian simvastatin survival study,” *Archives of Internal Medicine*, vol. 159, no. 22, pp. 2661–2667, 1999.

[35] J.-L. Chiasson, R. G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and M. Laakso, “Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial,” *Journal of the American Medical Association*, vol. 290, no. 4, pp. 486–494, 2003.

[36] W. C. Knowler, E. Barrett-Connor, S. E. Fowler et al., “Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin,” *The New England Journal of Medicine*, vol. 346, no. 6, pp. 393–403, 2002.

[37] J. S. Torgerson, J. Hauptman, M. N. Boldrin, and L. Sjöström, “XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients,” *Diabetes Care*, vol. 27, no. 1, pp. 155–161, 2004.

[38] C. X. Romero, T. E. Romero, J. C. Shlay, L. G. Ogden, and D. Dabelea, “Changing trends in the prevalence and disparities of obesity and other cardiovascular disease risk factors in three racial/ethnic groups of USA adults,” *Advances in Preventive Medicine*, vol. 2012, Article ID 172423, 8 pages, 2012.

[39] M. R. Goldstein, L. Mascitelli, and F. Pezzetta, “On treating metabolic syndrome: emphasise lifestyle change,” *The Lancet Oncology*, vol. 11, no. 5, article 415, 2010.

[40] T. Wilsgaard and B. K. Jacobsen, “Lifestyle factors and incident metabolic syndrome. The Tromsø Study 1979–2001,” *Diabetes Research and Clinical Practice*, vol. 78, no. 2, pp. 217–224, 2007.

[41] R. E. Kirk, *Experimental Design: Procedures for the Behavioral Sciences*, Brooks/Cole, Belmont, Mass, USA, 1982.

[42] A. Basu, N. M. Betts, A. Mulugeta, C. Tong, E. Newman, and T. J. Lyons, “Green tea supplementation increases glutathione and plasma antioxidant capacity in adults with the metabolic syndrome,” *Nutrition Research*, vol. 33, no. 3, pp. 180–187, 2013.

[43] A. E. Vieira Senger, C. H. Schwane, I. Gomes, and M. G. Valle Gottlieb, “Effect of green tea (Camellia sinensis) consumption on the components of metabolic syndrome in elderly,” *The Journal of Nutrition, Health & Aging*, vol. 16, no. 9, pp. 738–742, 2012.

[44] S. Bérubé-Parent, C. Pelletier, J. Doré, and A. Tremblay, “Effects of encapsulated green tea and Guarana extracts containing...
a mixture of epigallocatechin-3-gallate and caffeine on 24 h energy expenditure and fat oxidation in men,” British Journal of Nutrition, vol. 94, no. 3, pp. 432–436, 2003.

[45] A. M. Hill, A. M. Coates, J. D. Buckley, R. Ross, F. Thielecke, and P. R. C. Howe, “Can EGCG reduce abdominal fat in obese subjects?” Journal of the American College of Nutrition, vol. 26, no. 4, pp. 396S–402S, 2007.

[46] K. C. Maki, M. S. Reeves, M. Farmer et al., “Green tea catechin consumption enhances exercise-induced abdominal fat loss in overweight and obese adults,” Journal of Nutrition, vol. 139, no. 2, pp. 264–270, 2009.

[47] T. Komatsu, M. Nakamori, K. Komatsu et al., “Oolong tea increases energy metabolism in Japanese females,” Journal of Medical Investigation, vol. 50, no. 3-4, pp. 170–175, 2003.

[48] W. Rumpler, J. Seale, B. Clevidence et al., “Oolong tea increases metabolic rate and fat oxidation in men,” Journal of Nutrition, vol. 131, no. 11, pp. 2848–2852, 2001.

[49] P. Pietta, P. Simonetti, C. Gardana, A. Brusamolino, P. Morazzoni, and E. Bombardelli, “Relationship between rate and extent of catechin absorption and plasma antioxidant status,” Biochemistry and Molecular Biology International, vol. 46, no. 5, pp. 895–903, 1998.

[50] R. Hursel, W. Viechtbauer, A. G. Dulloo et al., “The effects of catechin rich teas and caffeine on energy expenditure and fat oxidation: a meta-analysis,” Obesity Reviews, vol. 12, no. 7, pp. e573–e581, 2011.

[51] M. S. Beaudoin, B. Allen, G. Mazzetti, P. J. Sullivan, and T. E. Graham, “Caffeine ingestion impairs insulin sensitivity in a dose-dependent manner in both men and women,” Applied Physiology, Nutrition, and Metabolism, vol. 38, no. 2, pp. 140–147, 2013.

[52] G. Belcaro, M. Cesarone, E. Silvia et al., “Daily consumption of reliv glucaffectÔ for 8 weeks significantly lowered blood glucose and body weight in 50 subjects,” Phytotherapy Research, vol. 23, no. 12, pp. 275–281, 2009.

[53] N. Boon, “Health potential for functional green teas?” International Journal for Vitamin and Nutrition Research, vol. 78, no. 6, pp. 275–281, 2008.

[54] T. Adar, A. Ben Yáčov, G. Lalazar et al., “Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells,” Clinical and Experimental Immunology, vol. 167, no. 2, pp. 252–260, 2012.

[55] N. Gupta, K. Goel, P. Shah, and A. Misra, “Childhood obesity in developing countries: epidemiology, determinants, and prevention,” Endocrine Reviews, vol. 33, no. 1, pp. 48–70, 2012.

[56] A. Nguyen Dinh Cat and F. Jaisser, “Extrarenal effects of aldosterone,” Current Opinion in Nephrology and Hypertension, vol. 21, no. 2, pp. 147–156, 2012.

[57] L. Soares-Miranda, G. Sandercock, S. Vale et al., “Metabolic syndrome, physical activity and cardiac autonomic function,” Diabetes/Metabolism Research and Reviews, vol. 28, no. 4, pp. 363–369, 2012.

[58] I. Stelzer, S. Zelzer, R. B. Raggam et al., “Link between leptin and interleukin-6 levels in the initial phase of obesity related inflammation,” Translational Research, vol. 159, no. 2, pp. 118–124, 2012.

[59] A. Barac, H. Wang, N. M. Shara et al., “Markers of inflammation, metabolic risk factors, and incident heart failure in American Indians: the strong heart study,” Journal of Clinical Hypertension, vol. 14, no. 1, pp. 13–19, 2012.